Ebola virus has a high mortality rate. At present, more than 3000 patients have been confirmed to be infected. MSD Ebola virus vaccine has been approved for marketing. Ervebo will be the first approved Ebola virus vaccine in the world!
&# 8203;&# 8203;&# 8203;&# 8203;&# 8203;&# 8203;
Ebola is a very rare virus. It is a general term used to call a group of viruses belonging to the Ebola virus family of fibroviridae. It can cause severe infectious disease of Ebola hemorrhagic fever in humans, with high mortality. The main causes of death are stroke, myocardial infarction, low blood volume shock or multiple organ failure.
In an outbreak in Congo, more than 2000 people died of Ebola virus infection. Now, it has become the second most prevalent virus in the world. According to the data of the World Health Organization, since the outbreak of the epidemic in Congo on August 1, 2018, more than 3000 patients have been confirmed to be infected.
Today, MRK. US announced that the human pharmaceutical products Committee (CHMP) of the European Drug Administration (EMA) recommended conditional approval of the company's Ebola vaccine ervebo (V920) to prevent diseases caused by Ebola virus in people aged 18 and over. If approved, ervebo will be the world's first approved Ebola virus vaccine.
Compared with other Ebola vaccines, the preventive effect can only be maintained for about 6 months. The long-term protection of ervebo will undoubtedly play a positive role in combating the Ebola epidemic in the future. Previously, the U.S. FDA has granted ervebo breakthrough therapy recognition and priority review qualification, and is expected to reply to its listing application before March 14 next year.